Q3 2024
Released Oct 29, 2024, before the open
10-Q filed Nov 4, 2024, 36 days after period end · 0000078003-24-000191
Q3 2024 · 10-Q
Revenue$17.70B$17.70B +31.2% vs Q3 2023+33.3% vs Q2 2024
Net Income$4.47B$4.47B N/M vs Q3 2023+10,790.2% vs Q2 2024
EPS Diluted$0.78$0.78 N/M vs Q3 2023+7,700.0% vs Q2 2024
Operating Cash Flowderived$6,714,000,000+94.3%
Free Cash Flowderived$6,063,000,000+129.1%
Margins · derived
Net margin25.2%+42.9 pt vs Q3 2023
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $17.70B | $13.49B | $22.64B | $24.04B |
| Net Income | $4.47B | -$2.38B | $8.61B | $8.15B |
| EPS Diluted | $0.78 | -$0.42 | $1.51 | $1.42 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR